Last reviewed · How we verify
mix of AllerT1-T2-T3
mix of AllerT1-T2-T3 is a Small molecule drug developed by Anergis. It is currently in Phase 1 development. Also known as: AllerT.
At a glance
| Generic name | mix of AllerT1-T2-T3 |
|---|---|
| Also known as | AllerT |
| Sponsor | Anergis |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mix of AllerT1-T2-T3 CI brief — competitive landscape report
- mix of AllerT1-T2-T3 updates RSS · CI watch RSS
- Anergis portfolio CI
Frequently asked questions about mix of AllerT1-T2-T3
What is mix of AllerT1-T2-T3?
mix of AllerT1-T2-T3 is a Small molecule drug developed by Anergis.
Who makes mix of AllerT1-T2-T3?
mix of AllerT1-T2-T3 is developed by Anergis (see full Anergis pipeline at /company/anergis).
Is mix of AllerT1-T2-T3 also known as anything else?
mix of AllerT1-T2-T3 is also known as AllerT.
What development phase is mix of AllerT1-T2-T3 in?
mix of AllerT1-T2-T3 is in Phase 1.
Related
- Manufacturer: Anergis — full pipeline
- Also known as: AllerT
- Compare: mix of AllerT1-T2-T3 vs similar drugs
- Pricing: mix of AllerT1-T2-T3 cost, discount & access